Ceralasertib in combination with Imfinzi (durvalumab) did not meet the primary endpoint of overall survival (OS) in the phase ...

AstraZeneca said on Monday that a late‑stage trial testing Imfinzi in combination ‍with ceralasertib failed to improve ...

(RTTNews) - British drug major AstraZeneca Plc (AZN, AZN.L) announced Monday that its Imfinzi (durvalumab) has been approved in the European Union as first and only immunotherapy for limited-stage ...

AstraZeneca has picked off another label expansion for its cancer blockbuster Imfinzi (durvalumab) as the FDA has blessed the PD-L1 inhibitor for limited-stage small cell lung cancer (LS-SCLC) ...

AstraZeneca’s LATIFY phase 3 trial evaluating ceralasertib in combination with Imfinzi did not meet its primary endpoint of overall survival in ...

The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...

The approval was supported by the randomized, double-blind, placebo-controlled phase 3 ADRIATIC study. Results showed durvalumab reduced the risk of death by 27% and disease progression or death by 24 ...

AstraZeneca (NASDAQ:AZN) announced Friday that the U.S. Food and Drug Administration (FDA) had approved another indication for its anti-PD-L1 immunotherapy Imfinzi (durvalumab) in lung cancer. The ...

AstraZeneca AZN announced that the FDA expanded the label of its blockbuster cancer drug Imfinzi for a fourth indication in lung cancer. The FDA approved Imfinzi in combination with platinum-based ...

The approval of Imfinzi was granted based on results from the pivotal ADRIATIC Phase III trial which demonstrated statistically significant and clinically meaningful results for its dual primary ...

When Ed O. went to the ER for shortness of breath and trembling, he never imagined he’d receive a diagnosis of unresectable (inoperable) Stage III non-small cell lung cancer (NSCLC). The news left him ...

AstraZeneca said on Monday that a late‑stage trial testing its blockbuster therapy Imfinzi in combination with its experimental drug ceralasertib failed to improve the overall survival of patients ...